Latest Ratios: P/E Ratio -0.8x · EV/EBITDA N/A · ROE -74.0%. (2018–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $19M | $13M | $246M | $387M | $915M | $3.2B | — | — | — |
| Enterprise Value | $11M | $6M | $240M | $380M | $905M | $3.2B | — | — | — |
| P/E Ratio → | -0.83 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.94 | 0.72 | 6.41 | 5.96 | 8.85 | 21.94 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -74.0% | -74.0% | -58.4% | -40.5% | -38.9% | -45.3% | -126.5% | — | — |
| ROA | -61.8% | -61.8% | -50.4% | -35.4% | -35.8% | -42.1% | -177.5% | -1091.6% | -704.8% |
| ROIC | -76.6% | -76.6% | -52.6% | -36.6% | -31.3% | -39.7% | — | — | — |
| ROCE | -76.1% | -76.1% | -58.3% | -41.6% | -38.1% | -45.5% | -117.2% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 0.10 | 0.10 | 0.08 | 0.02 | 0.04 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.39 | -0.16 | -0.10 | -0.09 | -0.03 | -1.00 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -657.91 | -657.91 | -334.08 | -256.69 | -220.86 | -53.92 | -10.90 | -6.42 | -38.87 |
Net cash position: cash ($9M) exceeds total debt ($2M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.06 | 5.06 | 7.70 | 11.92 | 11.98 | 30.38 | 4.16 | 0.02 | 0.48 |
| Quick Ratio | 5.06 | 5.06 | 7.70 | 11.92 | 11.98 | 30.38 | 4.16 | 0.02 | 0.48 |
| Cash Ratio | 4.98 | 4.98 | 7.59 | 11.65 | 11.82 | 30.19 | 3.44 | 0.01 | 0.25 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 2.7% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 2.7% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $1M | $25M | $28M | $31M | $28M | $31M | $29M | $685164 |
Critical liquidity and dilution
Based on reported figures, the company's price-to-book ratio of 0.94 suggests that the market is currently valuing the firm at a discount to its net asset value, which is typical for clinical-stage biotechs facing significant binary risk and a rapidly depleting cash runway.
The current P/B multiple indicates that investors are assigning little to no premium for the company's proprietary TMAB platform or the SNS-101 program. This valuation level suggests that the market is pricing in a high probability of further dilutive financing or potential clinical failure, rather than the long-term potential of the underlying technology.
According to recent SEC filings, the company's ROIC has remained deeply negative, reaching -5.0% in 2026Q1, which highlights the inherent difficulty of generating positive returns on invested capital while the firm remains in a pre-revenue, high-expenditure research and development phase.
The persistent decay in ROIC over the last ten quarters reflects the heavy capital investment required to advance the SNS-101 program without any offsetting commercial income. This trend warrants further investigation into whether the company's capital allocation strategy can pivot toward more efficient milestones before the current liquidity buffer is exhausted.
As reported in financial statements, the current ratio has compressed significantly from 14.39 in 2026Q1 to 5.06 by 2025Q4, signaling a rapid reduction in the firm's ability to cover short-term obligations as cash reserves are consumed by ongoing clinical trial and operational expenses.
While the current ratio remains numerically above 1.0, the rapid decline suggests that the company's liquidity position is becoming increasingly fragile. Investors should monitor the burn rate closely, as the current cash position may not provide sufficient runway to reach the next major clinical data readout without an immediate capital raise.
Based on reported figures, the current ratio is a misleading metric for this business model, as it fails to account for the lumpy nature of clinical trial accruals and the lack of recurring revenue, which obscures the true operational runway of the firm.
Analysts often rely on the current ratio to assess solvency, but for a pre-revenue biotech, this metric ignores the fact that the majority of current assets are cash that is being rapidly depleted by fixed R&D commitments. A more appropriate metric would be the 'cash burn rate' relative to the next clinical milestone, which provides a clearer picture of the company's survival timeline than standard liquidity ratios.
Includes 30+ ratios · 8 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SNSE stock.
Sensei Biotherapeutics, Inc.'s current P/E ratio is -0.8x. This places it at the 50th percentile of its historical range.
Sensei Biotherapeutics, Inc.'s return on equity (ROE) is -74.0%. The historical average is -63.9%.
Based on historical data, Sensei Biotherapeutics, Inc. is trading at a P/E of -0.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.